Xi Huang

Xi Huang

Auto-generated profile, based on publicly available information

Xi Huang

Department of Ophthalmology and Research Laboratory of Macular Disease, West China Hospital, Sichuan University, Chengdu 610041, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
XLXuanru Lin
Xuanru Lin
LYLi Yang
Li Yang
GWGang Wang
Gang Wang
FZFuming Zi
Fuming Zi
HYHaimeng Yan
Haimeng Yan
ZCZhen Cai
Zhen Cai
Interleukin-32 promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells

26 April 2018 in Oncology Letters
Verified
Journal Article
Open access
PDF file
SLSen Lu
Sen Lu
CLCaizhao Lin
Caizhao Lin
XCXiaobin Cheng
Xiaobin Cheng
HHHanju Hua
Hanju Hua
TXTao Xiang
Tao Xiang
XHXi Huang
Xi Huang
It has previously been reported that cardamonin is able to regulate glycometabolism and vasodilation whilst also exhibiting anti‑inflammatory and antitumor properties. The antitumor effect of cardamonin is multifaceted, and so it is necessary to investigate the antitumor mechanisms of cardamonin at the molecular level. Cardamonin alters chemotherapy‑resistant colon cancer cell growth; however, the underlying mechanism is unknown. The present study was conducted to investigate the effect of cardamonin on chemotherapy‑resistant colon cancer cells and the possible mechanisms of action. Cardamonin significantly suppressed the growth of chemotherapy‑resistant colon cancer cells, induced apoptosis and promoted caspase‑3/9 activity and Bax protein expression in 5‑fluorouracil (5‑FU)‑resistant HCT‑116 cells. Cardamonin significantly suppressed c‑MYC, octamer‑binding transcription factor 4, cyclin E, testes‑specific protease 50 and nuclear factor‑κB protein expression in 5‑FU‑resistant HCT‑116 cells. The findings of the present study demonstrate that cardamonin suppresses chemotherapy‑colon cancer cell via the NF‑κB pathway in vitro.

1 April 2018 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
LYLi Yang
Li Yang
JCJing Chen
Jing Chen
XHXi Huang
Xi Huang
EZEnfan Zhang
Enfan Zhang
JHJingsong He
Jingsong He
ZCZhen Cai
Zhen Cai

31 July 2024 in Cell Proliferation
Verified
Journal Article
Open access
XXXiaoxiao Xu
Xiaoxiao Xu
YFYanyan Fu
Yanyan Fu
DLDelun Luo
Delun Luo
LZLina Zhang
Lina Zhang
XHXi Huang
Xi Huang
MZMeixia Zhang
Meixia Zhang
Retinal ischemia/reperfusion injury (RI/R) is a common pathological process in ophthalmic diseases, which can cause severe visual impairment. The mechanisms underlying RI/R damage and repair are still unclear. Scholars are actively exploring effective intervention strategies to restore impaired visual function. With the development of nucleic acid nanomaterials, tetrahedral framework nucleic acids (tFNAs) have shown promising therapeutic potential in various fields such as stem cells, biosensors, and tumour treatment due to their excellent biological properties. Besides, miRNA‐22‐3p (miR‐22), as an important regulatory factor in neural tissue, has been proven to have positive effects in various neurodegenerative diseases. By stably constructing a complex of tetrahedral framework nucleic acids miR22 (tFNAs‐miR22), we observed that tFNAs‐miR22 had a positive effect on the repair of RI/R injury in retinal neural tissue. Previous studies have shown that tFNAs can effectively deliver miR‐22 into damaged retinal neurons, subsequently exerting neuroprotective effects. Interestingly, we found that there was a certain synergistic effect between tFNAs and miR‐22. tFNAs‐miR22 can selectively activated the ERK1/2 signalling pathway to reduce neuronal apoptosis, accelerate cell proliferation, and restore synaptic functional activity. In this study, we established a simple yet effective small molecule drug for RI/R treatment which may become a promising neuroprotectant for treating this type of vision impairment disease in the future.

8 May 2025 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
GSGongpeng Sun
Gongpeng Sun
HLHong Luo
Hong Luo
QRQibo Ran
Qibo Ran
YWYe Wei
Ye Wei
YZYi Zhang
Yi Zhang
MZMeixia Zhang
Meixia Zhang

18 September 2019 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
CLChen Liang
Chen Liang
LPLan Ya Peng
Lan Ya Peng
MZMing Zou
Ming Zou
XCXuemei Chen
Xuemei Chen
YCYingying Chen
Yingying Chen
XHXi Huang
Xi Huang
Purpose To determine whether the GNAQ/11 mutation correlated with the outcome of patients with uveal melanoma (UM) when genetic heterogeneity was considered. Methods We performed a retrospective study of sixty-seven patients with UM. The heterogeneity of GNAQ/11 was examined by using droplet digital PCR. The correlation between metastasis and heterogeneity of the GNAQ/11 mutation was analysed. Disease free survival curves were constructed using the Kaplan-Meier method, and the Wilcoxon log-rank test was used to compare the curves. Results The GNAQ/11 mutation ratio was varied between each case. Among these patients, 28.35% of them harboured homogeneous mutation of GNAQ/11, 62.69% present heterogeneous mutation and 8.96% didn’t present either GNAQ or GNA11 mutation. The tumour with heterogeneous mutation of GNAQ/11 has a higher metastatic rate than that with homogeneous mutation (13/29 vs 1/18, p=0.027). In Kaplan-Meier analysis, metastasis-free survival was not significantly associated with either homogeneous or heterogeneous mutation of GNAQ/11. Conclusion The mutation ratio of GNAQ/11 in UM was quite variable. The tumour with heterogeneous mutation of GNAQ/11 is more likely to develop a poor prognosis than that with homogeneous mutation of GNAQ/11.